These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
461 related items for PubMed ID: 21741847
1. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. Maezaki H, Banno Y, Miyamoto Y, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Sasaki M, Tsubotani S, Tani A, Funami M, Yamamoto Y, Tawada M, Aertgeerts K, Yano J, Oi S. Bioorg Med Chem; 2011 Aug 01; 19(15):4482-98. PubMed ID: 21741847 [Abstract] [Full Text] [Related]
2. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554. Banno Y, Miyamoto Y, Sasaki M, Oi S, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Tsubotani S, Tani A, Funami M, Tawada M, Yamamoto Y, Aertgeerts K, Yano J, Maezaki H. Bioorg Med Chem; 2011 Aug 15; 19(16):4953-70. PubMed ID: 21764322 [Abstract] [Full Text] [Related]
3. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, Ishige T, Shima K, Nabeno M, Abe Y, Anabuki J, Soejima A, Yoshida K, Takashina Y, Ishii S, Kiuchi S, Fukuda S, Tsutsumiuchi R, Kosaka K, Murozono T, Nakamaru Y, Utsumi H, Masutomi N, Kishida H, Miyaguchi I, Hayashi Y. Bioorg Med Chem; 2012 Oct 01; 20(19):5705-19. PubMed ID: 22959556 [Abstract] [Full Text] [Related]
4. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Furuta Y, Sakai M, Horiguchi M, Masui Y, Okazaki K, Sato Y, Nakahira H. Bioorg Med Chem; 2012 Oct 01; 20(19):5864-83. PubMed ID: 22938786 [Abstract] [Full Text] [Related]
5. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. Deng J, Peng L, Zhang G, Lan X, Li C, Chen F, Zhou Y, Lin Z, Chen L, Dai R, Xu H, Yang L, Zhang X, Hu W. Eur J Med Chem; 2011 Jan 01; 46(1):71-6. PubMed ID: 21106276 [Abstract] [Full Text] [Related]
6. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability. Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Umezome T, Sakurai Y, Sawada N, Tadano J, Sugaru E, Ono M, Hirose Y, Nakahira H. Bioorg Med Chem; 2015 Feb 15; 23(4):779-90. PubMed ID: 25596166 [Abstract] [Full Text] [Related]
7. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA. Eur J Pharmacol; 2011 Feb 10; 652(1-3):157-63. PubMed ID: 20540938 [Abstract] [Full Text] [Related]
8. Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554. Maezaki H, Tawada M, Yamashita T, Banno Y, Miyamoto Y, Yamamoto Y, Ikedo K, Kosaka T, Tsubotani S, Tani A, Asakawa T, Suzuki N, Oi S. Bioorg Med Chem Lett; 2017 Aug 01; 27(15):3565-3571. PubMed ID: 28579121 [Abstract] [Full Text] [Related]
9. Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor. Miyamoto Y, Banno Y, Yamashita T, Fujimoto T, Oi S, Moritoh Y, Asakawa T, Kataoka O, Yashiro H, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Tsubotani S, Tani A, Sasaki M, Funami M, Amano M, Yamamoto Y, Aertgeerts K, Yano J, Maezaki H. J Med Chem; 2011 Feb 10; 54(3):831-50. PubMed ID: 21218817 [Abstract] [Full Text] [Related]
10. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors. Sharma M, Gupta M, Singh D, Kumar M, Kaur P. Chem Biol Drug Des; 2012 Dec 10; 80(6):918-28. PubMed ID: 22943413 [Abstract] [Full Text] [Related]
18. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor. Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S. Eur J Pharmacol; 2011 Mar 25; 655(1-3):99-107. PubMed ID: 21262219 [Abstract] [Full Text] [Related]
19. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. Gupta RC, Chhipa L, Mandhare AB, Zambad SP, Chauthaiwale V, Nadkarni SS, Dutt C. Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5021-5. PubMed ID: 19643608 [Abstract] [Full Text] [Related]
20. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? Juillerat-Jeanneret L. J Med Chem; 2014 Mar 27; 57(6):2197-212. PubMed ID: 24099035 [Abstract] [Full Text] [Related] Page: [Next] [New Search]